← Markets

4D Molecular Therapeutics, Inc.

FDMT · NASDAQ

Market closed$10.99$0.150000 (+1.38%)After hours $10.29 · -6.35%

Key statistics

Previous close$10.84
Open$10.46
Day high$11.28
Day low$10.29
52-week high$14.00
52-week low$4.15
Market cap574.52M
Volume578.17K
Average volume854.29K
P/E ratio-4.28
Forward P/E—
EPS-2.57
Dividend yield0.00%

Market context

Why it moved

FDMT rose after 4D Molecular Therapeutics announced positive two-year data from its PRISM Phase 2b clinical trial showing that its gene therapy 4D-150 maintained visual acuity and significantly reduced treatment burden in wet AMD patients, with a favorable long-term safety profile.

QuiverquantMarketbeatMarketbeatCoinglassBusiness Insider

What is happening

Recent company-specific developments and publisher coverage.

July 18, 20264D Molecular Therapeutics closed modestly higher during the regular session, but shares are sliding over 6% in after-hours trading, pulling back toward session lows. The company's most recent headline was a routine RSU grant to six new employees under its 2025 Inducement Plan — a signal of continued hiring, but not a market catalyst. Investor focus remains on CEO David Kirn's pre-arranged 10b5-1 sale of ~58,333 shares (~$737K) earlier in the week, alongside broader biotech pressure as the S&P 500 and Nasdaq declined on AI valuation concerns and escalating U.S.-Iran tensions. Analyst targets remain significantly above current levels, ranging from $17–$36.

1.3838

July 16, 20264D Molecular Therapeutics closed essentially flat amid investor focus on a recent CEO insider sale — CEO David Kirn sold 58,333 shares worth ~$737K on July 9–10 under a pre-arranged 10b5-1 plan, executed at prices between $12.01 and $12.87, above the current trading level. Despite the insider activity, analysts remain constructive: H.C. Wainwright holds a Buy rating with a $36 price target, supported by ahead-of-schedule completion of enrollment in both Phase 3 4FRONT-1 and 4FRONT-2 trials for its 4D-150 gene therapy. UBS also flagged biotech as a key sector allocation amid improving earnings revisions and M&A recovery.

-0.1709

July 14, 20264D Molecular Therapeutics gained over 3% during the regular session, though shares are giving back those gains in after-hours trading, falling roughly 4.6% to around $11.16. Investor attention is drawn to a disclosed 10b5-1 plan sale by CEO David Kirn, who sold 58,333 shares valued at approximately $737K across July 9–10, a pre-arranged transaction that nonetheless adds a layer of insider sentiment scrutiny. The moves come against a backdrop of recently reported Q1 2026 results showing a narrower loss per share, while the broader healthcare sector faces headwinds into Q2 earnings season.

3.5398

July 14, 20264D Molecular Therapeutics tumbled sharply, closing down over 8%, as the session was weighed down by a combination of Q1 2026 earnings-related sentiment and a broad market risk-off environment. Sources cited a narrower-than-expected loss per share but the stock nonetheless declined, possibly reflecting investor disappointment with revenue trends or forward guidance. The broader backdrop added pressure, with U.S.-Iran tensions driving oil prices higher, chip stocks selling off, and the S&P 500 and Nasdaq broadly lower on the day; healthcare sector ETF XLV also closed modestly lower. Separately, recent Form 144 filings revealed continued insider share sales by CEO David Kirn and a planned Goldman Sachs liquidation of legacy shares, which may have compounded near-term selling pressure.

-8.2047

July 11, 20264D Molecular Therapeutics fell sharply, underperforming the broader healthcare sector as insider selling activity weighed on sentiment — a Form 144 filing revealed a planned sale of ~15,725 Class A shares by Goldman Sachs, following CEO David Kirn's June disposals of over 116,000 shares worth more than $1.2 million. The decline contrasts with Jim Cramer's recent bullish call on biotech as a market-leading group, and comes amid broader biotech headwinds including Medicaid funding cuts from the One Big Beautiful Bill Act that analysts warn will cloud revenue projections for drug developers.

-4.4996

July 3, 20264D Molecular Therapeutics gained amid a flurry of company-specific catalysts, as investors continued to digest the June 29 announcement that the 4FRONT-2 global Phase 3 trial of 4D-150 in wet AMD completed enrollment roughly four months ahead of schedule with over 500 patients — triggering an 11% surge on that day. Simultaneously, the company secured a $200M credit facility from Hercules Capital, drawing $20M at closing to fund advancing programs. Tailwinds from healthcare being the top-performing S&P sector on the day, aided by a soft June jobs report easing Fed rate-hike fears, supported sentiment. However, shares slipped 3.69% in after-hours trade, and investors are eyeing a key upcoming catalyst: a 2-year PRISM Phase 2b data presentation at the ASRS meeting on July 18.

2.4429

July 2, 20264D Molecular Therapeutics shares fell nearly 5%, giving back a portion of the prior session's 11% surge triggered by the completion of Phase 3 enrollment in its 4FRONT-2 wet AMD gene therapy trial four months ahead of schedule. The pullback appears to reflect profit-taking after the outsized move, with investors also digesting the company's concurrent $200 million Hercules Capital credit facility — including an initial $20 million draw — and an upcoming ASRS podium presentation on July 18 featuring 2-year PRISM Phase 2b follow-up data. Elevated short interest of ~24% and an active $400 million shelf registration continue to weigh as overhang risks even as two Phase 3 readouts in 2027 keep the clinical narrative constructive.

-4.5865

July 1, 20264D Molecular Therapeutics shares rallied on the back of a pair of catalysts announced over two consecutive days. The company completed global enrollment for its 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD roughly four months ahead of schedule and with over-enrollment (N>500), while simultaneously securing a strategic credit facility of up to $200 million from Hercules Capital — with $20 million drawn at closing — providing a meaningful runway to fund its advancing Phase 3 programs. Adding further momentum, 4DMT announced it will present 2-year follow-up data from the PRISM Phase 2b trial at the ASRS annual meeting in July, keeping clinical catalysts front-of-mind for investors ahead of dual Phase 3 readouts expected in 2027.

3.2609

Foreign Policy Journal · July 19, 20264D Molecular Therapeutics (NASDAQ: FDMT) Reports Two-Year Gene Therapy Data Showing 87% Treatment Burden Reduction In Wet AMD PatientsQuiver Quantitative · July 18, 20264D Molecular Therapeutics Announces Positive Two-Year PRISM Phase 2b Data for 4D-150 in Wet AMDStock Titan · July 18, 2026A single 4D-150 dose cut wet AMD treatment burden 78%Pluang · July 18, 20264DMT reports positive 2-year data for 4D-150 ge...Simply Wall Street · May 11, 2026Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter ReportSeeking Alpha · December 19, 20254D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)
Mt Newswire · June 29, 20264D Molecular Therapeutics Completes Enrollment in Phase 3 Wet AMD Trial
Benzinga · June 29, 20264D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration
Benzinga · May 7, 20264D Molecular Therapeutics Files Prospectus To Offer And Sell Up To $400M Of Securities In Multiple Offerings
Benzinga · May 7, 20264D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate
Benzinga · March 19, 2026RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35
Mt Newswire · March 19, 2026RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk
Benzinga · March 18, 2026UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate
Mt Newswire · March 18, 20264D Molecular Therapeutics Full-Year 2025 Loss Narrows, Revenue Rises

Peers

S&P 500SPX · $7,457.69-1.01%uniQure N.V.QURE · $40.25+2.26%Acacia Research CorporationACTG · $4.54+1.57%Biogen Inc.BIIB · $205.99-1.40%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%Immunome, Inc.IMNM · $22.32+0.54%Trevi Therapeutics, Inc.TRVI · $19.07+9.85%Nurix Therapeutics, Inc.NRIX · $23.12+0.22%Ocugen, Inc.OCGN · $1.36-0.73%Design Therapeutics, Inc.DSGN · $12.57-0.32%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%